Get started
Author

Mohammed A. Aleskandarany

Observed names: Aleskandarany, Mohammed, M Aleskandarany, M. A. Aleskandarany, M. Aleskandarany, M.A. Aleskandarany, MA Aleskandarany, Mohamed Aleskandarany, Mohammad A. Aleskandarany, Mohammad Aleskandarany, MohammadA Aleskandarany, Mohammed A Alaskandarany, Mohammed A Aleskandarany, Mohammed Aleskandarany, MohammedA Aleskandarany, Mohammed A. Aleskandarany, Muhammed A. Aleskandarany
Observed institutions: Nottingham University Hospitals NHS Trust, University of Nottingham, Georgia State University, University of Derby, Stavanger University Hospital, Nottingham City Hospital, University of Ha'il, Queen's Medical Centre, Velindre Cancer Centre, Menoufia University, Cardiff University
ORCID: 0000-0001-5538-5946
Observed ORCID: 0000-0001-5538-5946
OpenAlex ID: A5001129686
Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes
2009 · Emad A. Rakha, Somaia E. Elsheikh, et al. · Clinical Cancer Research · 489
Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen
2009 · Hany Onsy Habashy, Desmond G. Powe, et al. · Breast Cancer Research and Treatment · 236
CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome
2007 · Somaia Elsheikh, Andrew R. Green, et al. · Breast Cancer Research and Treatment · 154
MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
2016 · Andrew R Green, Mohammed A Aleskandarany, et al. · British Journal of Cancer · 138
PDF
Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
2012 · Mohammed A Aleskandarany, Andrew R Green, et al. · Breast Cancer Research · 127
MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups
2010 · Mohammed A. Aleskandarany, Emad A. Rakha, et al. · Breast Cancer Research and Treatment · 110
Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine
2018 · Mohammed A. Aleskandarany, Michel E. Vandenberghe, et al. · Pathobiology · 108
Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis
2016 · Mohammad A. Aleskandarany, Rezvan Abduljabbar, et al. · Breast Cancer Research and Treatment · 102
Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKT–YB1–MDR1 Signaling Pathway
2016 · Dongliang Mo, Hongbo Fang, et al. · Cancer Research · 101
The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast
2009 · E.A. Rakha, M. Aleskandarany, et al. · European Journal of Cancer · 100
A CD44−/CD24+ phenotype is a poor prognostic marker in early invasive breast cancer
2011 · Mohamed A. H. Ahmed, Mohammed A. Aleskandarany, et al. · Breast Cancer Research and Treatment · 95
PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis
2009 · Mohammed A. Aleskandarany, Emad A. Rakha, et al. · Breast Cancer Research and Treatment · 95
MYC regulation of glutamine–proline regulatory axis is key in luminal B breast cancer
2017 · Madeleine L Craze, Hayley Cheung, et al. · British Journal of Cancer · 94
PDF
Heterogeneity of tumour‐infiltrating lymphocytes in breast cancer and its prognostic significance
2018 · Maryam Althobiti, Mohammed A Aleskandarany, et al. · Histopathology · 87
PDF
FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer
2011 · Hany Onsy Habashy, Emad A. Rakha, et al. · Breast Cancer Research and Treatment · 81
Breast cancer intratumour heterogeneity: current status and clinical implications
2018 · Chitra Joseph, Athanasia Papadaki, et al. · Histopathology · 78
Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study
2019 · Shristi Bhattarai, Sergey Klimov, et al. · Cancers · 74
PDF
Molecular Mechanisms Underlying Lymphovascular Invasion in Invasive Breast Cancer
2015 · Mohammed A. Aleskandarany, Sultan N. Sonbul, et al. · Pathobiology · 70
Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ
2017 · Islam Miligy, Priya Mohan, et al. · Histopathology · 69
An approach to the diagnosis of spindle cell lesions of the breast
2015 · Emad A Rakha, Mohammed A Aleskandarany, et al. · Histopathology · 65
Glutamate dehydrogenase (GLUD1) expression in breast cancer
2018 · Madeleine L. Craze, Rokaya El-Ansari, et al. · Breast Cancer Research and Treatment · 63
Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections
2017 · Abir A. Muftah, Mohammed A. Aleskandarany, et al. · Breast Cancer Research and Treatment · 63
PDF
Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study
2014 · Mohammed A. Aleskandarany, Ola H. Negm, et al. · Breast Cancer Research and Treatment · 63
Cten signals through integrin-linked kinase (ILK) and may promote metastasis in colorectal cancer
2011 · A Albasri, S Al-Ghamdi, et al. · Oncogene · 63
The nucleolar-related protein Dyskerin pseudouridine synthase 1 (DKC1) predicts poor prognosis in breast cancer
2020 · Khloud A. Elsharawy, Omar J. Mohammed, et al. · British Journal of Cancer · 62
PDF
Works count: 103
Citation count: 4,600
H-index: 40
I10-index: 84
Year
Topic
Type